RESEARCH STUDIES

The next generation of AG1 is clinically backed.

Our innovation is driven by our ongoing investments in research and clinical discovery. We ensure the benefits of our products are thoroughly researched and any claims are substantiated by multiple bodies of research on ingredients and the finished formula. The impact of AG1 Next Gen is not just experienced, it's measurable.*^1-4

One product, four gold-standard clinical trials.

AG1 Next Gen has been put to the test in multiple gold-standard clinical trials, consistently showing its efficacy in closing nutrient gaps and supporting gut health across diverse populations and study designs.*^1-4

One product, four gold-standard clinical trials.

Our research findings

NUTRITIONAL GAPS

AG1 Next Gen is clinically shown to fill common nutrient gaps even in healthy eaters.¹⁻⁴

WHY THIS MATTERS

In four randomized, placebo-controlled trials—meeting strict and widely accepted standards for clinical research—AG1 Next Gen demonstrated a statistically significant and positive impact on closing common nutrient gaps. These studies included participants with diverse diets, backgrounds, ages, and activity levels.¹⁻⁴

NUTRIENT LEVELS

AG1 Next Gen improves key nutrient levels within 3 months.¹

subjects drinking AG1 Next Gen had an increase in RBC folate.¹

WHY THIS MATTERS

Adequate micronutrients are needed to support the body in the production of energy, building proteins, and metabolizing food. They act as co-factors and individual building blocks. Maintaining consistent intake is key for overall health.*

increase in Vitamin C levels¹

WHY THIS MATTERS

Vitamin C supports the body's ability to combat oxidative stress and support immune defenses. It is a super antioxidant that plays a fundamental role in various physical and cellular processes.*

GUT HEALTH

AG1 Next Gen is clinically shown to enrich the gut microbiome.¹⁻³

Over

Average increase in healthy bacteria in the gut^1-3

WHY THIS MATTERS

Beneficial bacteria—such as the probiotic strains in AG1 Next Gen—are important for maintaining a healthy microbiome and play a key role in supporting overall gut health.*

BIOAVILABILITY

Key nutrients in AG1 Next Gen were shown to be quickly and easily absorbed into the body.⁴

Folate levels were significantly increased within 30 minutes of drinking AG1 Next Gen.⁴

WHY THIS MATTERS

AG1 Next Gen delivers key nutrients like folate, vitamin C, and zinc—in bioavailable forms the body can easily and readily utilize, maximizing their potential benefits.*

¹Triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
² Double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37.
³ Double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome assessments of 24 healthy adults with occasional GI distress ages 26-59.
⁴ Double-blind, randomized, placebo-controlled crossover clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.

What powers our research

There are many ways to study how nutrition impacts the body. In our clinical research, we use advanced tools and technologies—alongside our academic and clinical partners—to explore the connection between nutrient intake and microbiome composition.

Our Team

Our research team

Our in-house team of clinicians and scientists bring diverse expertise across nutrition, metabolism, microbiome, and related fields. We also collaborate with independent experts, academic institutions, and clinical partners to advance research and expand our understanding with cutting-edge technology.

The clinical research lifecycle

We’re proud to share that four clinical trials – rigorously designed, randomized, placebo-controlled trials – on the AG1 Next Gen formula have been completed. This is a major milestone in our scientific journey and one that underscores our long-standing commitment to evidence-based innovation.

Just like the trials themselves, the clinical research lifecycle is also rigorous, and it can be lengthy.

The process of undertaking a trial, analyzing the results, and publishing them can take years. But we know it’s worth the wait, because we’re committed to advancing science—not just for the sake of innovation, but to contribute meaningfully to advancing the science of nutrition and the microbiome forward.

How the trials were conducted

AG1’s diverse team of clinicians, researchers, and PhDs work together to build initial studies.
The team conducted pre-clinical trials to inform the clinical trials. Pre-clinical studies were intentionally conducted to better understand the biological activity and mechanisms of AG1 Next Gen — an approach that’s both common and foundational in the development of nutrition research. These early insights help inform the design of human clinical trials, enhancing scientific rigor and ensuring that future studies are strategically and effectively guided. Pre-clinical trials can take upwards of 8-10 months to design, implement and analyze the results.
We then partnered with independent contract research organizations (CROs)—the same groups trusted by other companies and academic institutions—to ensure data collection and analysis were objective and professionally managed.
To ensure scientific integrity and ethical compliance, each human study protocol was submitted for review and approval by an independent Institutional Review Board (IRB) prior to participant recruitment. IRB approval is a critical regulatory step that ensures the rights, safety, and well-being of study participants are protected, and that the research is conducted according to Good Clinical Practice (GCP) and applicable regulations. No human study began without formal IRB approval.
We then created detailed protocols with third-party scientists (also known as principal scientists) outlining specific criteria including the study population, endpoints, duration, measurements, and statistical plan. The research partners then recruited participants to ensure the most objective outcome for each study design. Participants and the third-party researchers in the trials were “blinded,” meaning they did not know they were taking AG1 or a placebo. As a part of the design, our scientists and statisticians helped determine the power of the study — which refers to the likelihood that the study would detect a true effect if one existed, ensuring the results would be scientifically meaningful and not due to chance.
Each study was conducted over varying lengths of time, designed specifically to help answer the research questions—whether AG1 could measurably impact specific markers such as nutrient status, or microbiome composition in various populations from healthy individuals, active people to those with occasional gut issues.

After the trials were completed

The institution that conducted the study analyzed and interpreted the results, and presented the findings to us. Given the volume and complexity of biomarker and microbiome data, we also partnered with advanced data science teams to ensure robust and accurate interpretation.
The data and research underwent strict scrutiny, not only from third-party scientists and statisticians, but also from our internal AG1 team including regulatory, research and legal teams.
Together, we identified the most meaningful and measurable insights—both about individual ingredients and the formula as a whole—that shaped the development and launch of AG1 Next Gen, and that continue to inform how we communicate the science behind our products.

What happens next

We are committed to advancing scientific research through a level of integrity that goes well beyond the basic requirements for publication. The next phase of the publishing process starts with submitting abstracts – another word for summaries – to annual conferences.
Once accepted, these submissions may be chosen for poster (a visual summary of research findings) or an oral presentation. Abstracts are typically published post-symposium, and the timing can vary depending on the scientific meeting.
We’ve recently had abstracts accepted at several national scientific conferences, including:
- 2025 American Physiology Summit (April 24–27), published here.
- 2025 American Society of Nutrition (May 31–June 3)
- 2025 American Society of Microbiology Annual Conference (June 19–23)
- 2025 The International Society of Sports Nutrition Annual International Conference (June 23-25)
- And more.
These abstracts are under embargo, meaning we can’t share them until they are presented at the conferences listed above. As they are published, we will update this page.
In parallel, AG1 is preparing full manuscripts containing more data from all four trials, which will be submitted to peer-reviewed journals over the coming months for publication.

Peer-reviewed research

At AG1, science is at the heart of everything we do. Our commitment to research goes beyond any single formulation - we invest in rigorous, ongoing clinical studies to explore the role of foundational nutrition in overall health.

Beyond sharing our findings, we work with leading researchers to submit study manuscripts to peer-reviewed scientific journals—contributing to the broader scientific dialogue on the vital role of nutrition and the microbiome in overall health. To date, our peer-reviewed publications include both literature reviews and research on the AG1 original formula, which you can explore here.

In addition, multiple clinical studies on AG1 Next Gen have been completed, and several abstracts have been accepted at upcoming national scientific conferences. As they are presented and published, we will update this page. In parallel, we are also working on several manuscripts which will be submitted to peer reviewed journals and published here upon acceptance.

JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION

The effects of AG1® supplementation on the gut microbiome of healthy adults: a randomized, double-blind, placebo-controlled clinical trial

This study investigated the effects of AG1® supplementation on the gut microbiome, GI tolerability, and clinical safety markers in healthy adults. After four weeks, AG1® enriched beneficial probiotic taxa, showed a potential improvement in digestive quality of life, and did not negatively impact stool consistency, bowel frequency, or clinical safety markers, demonstrating its safety for daily use.

Read paper

NUTRIENTS

Foundational Nutrition: Implications for Human Health

Human nutrition, and what can be considered “ideal” nutrition, is a complex, multi-faceted topic which many researchers and practitioners deliberate. While some attest that basic human nutrition is relatively understood, it is undeniable that a global nutritional problem persists.

Read paper

FRONTIERS

Nutrient synergy: definition, evidence, and future directions

Nutrient synergy refers to the concept that the combined effects of two or more nutrients working together have a greater physiological impact on the body than when each nutrient is consumed individually.

Read paper

NUTRACEUTICALS

The Novel Synbiotic, AG1®, Increases Short-Chained Fatty Acid Production in the Simulator of Human Intestinal Microbial Ecosystem (SHIME) Model®

Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms.

Read paper

APPLIED BIOSCIENCE

AG1®, a Novel Synbiotic, Demonstrates Superior Mineral Bioaccessibility and Bioavailability Compared to a Tablet Multivitamin and Mineral Supplement Using an In Vitro Model of the Upper Gastrointestinal Tract

While traditional multivitamin and mineral (MVM) supplements generally come in tablet form, new powder forms of MVM supplements are available with theoretically higher bioavailability relative to tablet MVM supplements. which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms. Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms. Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms.

Read paper

CURRENT ISSUES IN MOLECULAR BIOLOGY

AG1® Induces a Favorable Impact on Gut Microbial Structure and Functionality in the Simulator of Human Intestinal Microbial Ecosystem® Model

The study using the SHIME® model demonstrated that AG1® had a significant impact on the composition of the human gut microbiota, leading to differential enrichment of bacterial taxa and metabolic pathways, suggesting potential favorable effects on gut microbial composition following AG1® supplementation. Kirby et al 2024.

Read paper

MICROORGANISMS

AG1®, a Novel Synbiotic, Maintains Gut Barrier Function following Inflammatory Challenge in a Caco-2/THP1-Blue™ Co-Culture Model

This in vitro study assessed the impact of AG1, a synbiotic supplement, on gastrointestinal (GI) permeability following an inflammatory challenge. Using a human GI tract model, AG1 was found to significantly improve transepithelial electrical resistance (TEER), suggesting protective effects on GI permeability compared to a control. No significant differences in inflammatory markers were observed, and the beneficial effects may be driven by short-chain fatty acid (SCFA) production from AG1’s prebiotic and probiotic components.

Read paper

JOURNAL OF FUNCTIONAL FOODS

Changes in the fecal polar metabolome due to AG1 supplementation in the SHIME® model: A proof of principle study

Metabolomics is a critical approach to fully understand the metabolic repercussions of a nutritional supplement on the gut microbiota. Here, a proof of principle study was conducted via a metabolomic survey of polar metabolites to explore the effect of AG1 on the metabolic output of the human gut microbiota, in vitro, using the Simulator of the Human Intestinal Microbial Ecosystem® (SHIME)

Read paper

FAQS

What studies have been done on AG1 Next Gen?

AG1 Next Gen has been studied across multiple clinical trials, consistently demonstrating its effectiveness in closing common nutrient gaps and supporting gut health.

Triple-blind, randomized, placebo-controlled trial (105 healthy adults who consumed a Standard American Diet) measuring nutrient biomarkers and microbiome changes.
Double-blind, placebo-controlled crossover trial (20 highly active healthy adults) assessing nutrient gaps and microbiome changes.
Double-blind, placebo-controlled crossover trial (24 healthy adults with occasional digestive discomfort) assessing nutrient gaps and microbiome changes.
Double-blind, placebo-controlled crossover trial (16 healthy adults) measuring nutrient absorption and bioavailability.

What did the studies find?

At a high-level, AG1 Next Gen was clinically shown to close common nutrient gaps—areas where the average diet may fall short—and support gut health, two critical factors for overall health, energy, and daily function. These results were consistent across multiple gold-standard clinical trials studying a range of lifestyles, including healthy adults who ate a Standard American Diet, highly active adults, and healthy adults experiencing occasional digest discomfort.

After these studies concluded, the data and research underwent strict scrutiny from third-party scientists and statisticians, as well as our internal AG1 regulatory, research and legal teams. Together, we identified the most meaningful and measurable insights that shaped the development and launch of AG1 Next Gen. You can learn more on our Research page.

What is a “gold standard” clinical trial?

Is this research published in peer-reviewed journals?

Several AG1 reviews and studies have already been published in leading peer-reviewed journals, including Nutrients, Frontiers, Nutraceuticals, and the Journal of Functional Foods. In addition to publishing the methodology and results on our site, manuscripts covering results from the latest research studies on AG1 Next Gen are being prepared and will be submitted to peer-reviewed journals. The review process for publication is rigorous, and can take time given the evaluation includes an in-depth evaluation by a panel of independent experts. You can learn more about the clinical research lifecycle on our Research page.

When will more information from the AG1 Next Gen clinical trials be available?

In addition to the key findings that have already been shared, we are committed to advancing scientific research through a level of integrity that goes well beyond the basic requirements for publication. The next phase of the publishing process starts with submitting abstracts – another word for summaries – to annual conferences.

We’ve recently had abstracts accepted at several national scientific conferences, including:

2025 American Physiology Summit (April 24–27), published here.
2025 American Society of Nutrition (May 31–June 3)
2025 American Society of Microbiology Annual Conference (June 19–23)
2025 The International Society of Sports Nutrition Annual International Conference (June 23-25)
And more.

These abstracts are under embargo – meaning we can’t share them – until they are presented at the conferences listed above. As they are published, we will update this page. In parallel, AG1 is preparing full manuscripts containing more data from all four trials, which will be submitted to peer-reviewed journals over the coming months for publication.

What measures do you take to ensure the quality of AG1 Next Gen?

We’re proud to hold some of the highest standards in the supplement category. Since 2010, we have earned the trust of millions of people around the world with our relentless approach to quality, efficacy, and safety.

This includes rigorously testing AG1 for hundreds of contaminants, including heavy metals, allergens, and over 500 herbicides and pesticides. Through NSF Certified for Sport®, an independent third-party program that certifies dietary supplements are free from substances banned by major sporting organizations, we also test for over 280 banned substances, including stimulants, narcotics, diuretics, and masking agents.

You can read more about our standards and processes here.